Skip to main content
Fig. 2 | Stem Cell Research & Therapy

Fig. 2

From: Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagy

Fig. 2

Characterization of MenSCs and cytotoxic effects of sorafenib on MenSCs. A Tri-lineage differentiation potential of MenSCs. Scale bar: 100 µm. MenSCs used in this study exhibited good multidifferentiation potential. B Surface markers of MenSCs were analyzed by flow cytometry. MenSCs used in this work were positive for MSC surface markers CD29, CD73, CD90 and CD105 and negative for CD34, CD45, CD117, and human leukocyte antigen DR (HLA-DR). C Cell viability was determined using CCK-8 analysis after MenSCs were treated with sorafenib for 24, 48, and 72 h. D Cell viability was determined using Annexin V/ PI staining 72 h after MenSCs were treated with sorafenib (10 µM) under hypoxia. The results in C, D suggested that Sorafenib exerted a weak cytotoxic effect on MenSCs. **p < 0.01. ns represents not statistically significant

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512